<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Nelson Pediatrics ‚Äî Part XII: Immunology</title>
<link href="https://fonts.googleapis.com/css2?family=Playfair+Display:wght@400;700;900&family=DM+Sans:wght@300;400;500;600&family=DM+Mono:wght@400;500&display=swap" rel="stylesheet">
<style>
  :root {
    --bg: #0d1117;
    --surface: #161b22;
    --surface2: #1c2333;
    --border: #30363d;
    --accent: #e8a44a;
    --accent2: #5caaee;
    --accent3: #63d98a;
    --danger: #f07a7a;
    --text: #e6edf3;
    --text-muted: #8b949e;
    --text-dim: #484f58;
  }
  * { margin: 0; padding: 0; box-sizing: border-box; }
  body { background: var(--bg); color: var(--text); font-family: 'DM Sans', sans-serif; font-weight: 300; line-height: 1.75; min-height: 100vh; }
  body::before { content: ''; position: fixed; inset: 0; background-image: url("data:image/svg+xml,%3Csvg viewBox='0 0 256 256' xmlns='http://www.w3.org/2000/svg'%3E%3Cfilter id='noise'%3E%3CfeTurbulence type='fractalNoise' baseFrequency='0.9' numOctaves='4' stitchTiles='stitch'/%3E%3C/filter%3E%3Crect width='100%25' height='100%25' filter='url(%23noise)' opacity='0.04'/%3E%3C/svg%3E"); pointer-events: none; z-index: 0; opacity: 0.4; }
  .page-wrap { position: relative; z-index: 1; max-width: 920px; margin: 0 auto; padding: 0 24px 80px; }
  .hero { padding: 72px 0 48px; border-bottom: 1px solid var(--border); margin-bottom: 48px; position: relative; overflow: hidden; }
  .hero::after { content: 'XII'; position: absolute; right: -10px; top: 10px; font-family: 'Playfair Display', serif; font-size: 160px; font-weight: 900; color: var(--border); line-height: 1; pointer-events: none; user-select: none; }
  .hero-tag { display: inline-flex; align-items: center; gap: 8px; background: rgba(232,164,74,0.1); border: 1px solid rgba(232,164,74,0.3); color: var(--accent); font-family: 'DM Mono', monospace; font-size: 11px; letter-spacing: 0.12em; text-transform: uppercase; padding: 5px 12px; border-radius: 4px; margin-bottom: 20px; }
  .hero-tag::before { content: ''; width: 6px; height: 6px; border-radius: 50%; background: var(--accent); animation: pulse 2s ease-in-out infinite; }
  @keyframes pulse { 0%, 100% { opacity: 1; transform: scale(1); } 50% { opacity: 0.4; transform: scale(0.8); } }
  .hero h1 { font-family: 'Playfair Display', serif; font-size: clamp(28px, 4.5vw, 48px); font-weight: 900; line-height: 1.1; margin-bottom: 12px; color: var(--text); }
  .hero h1 span { color: var(--accent); }
  .hero-sub { font-size: 15px; color: var(--text-muted); max-width: 560px; margin-bottom: 28px; }
  .hero-meta { display: flex; gap: 24px; flex-wrap: wrap; }
  .meta-pill { display: flex; align-items: center; gap: 6px; font-size: 12px; color: var(--text-muted); font-family: 'DM Mono', monospace; }
  .meta-pill .dot { width: 8px; height: 8px; border-radius: 50%; }
  .search-bar { position: sticky; top: 0; z-index: 100; background: rgba(13,17,23,0.92); backdrop-filter: blur(12px); border-bottom: 1px solid var(--border); padding: 12px 0; margin-bottom: 36px; }
  .search-inner { max-width: 920px; margin: 0 auto; padding: 0 24px; display: flex; align-items: center; gap: 12px; }
  .search-input { flex: 1; background: var(--surface); border: 1px solid var(--border); border-radius: 8px; padding: 8px 14px 8px 36px; color: var(--text); font-family: 'DM Sans', sans-serif; font-size: 14px; outline: none; transition: border-color 0.2s; background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='16' height='16' viewBox='0 0 24 24' fill='none' stroke='%238b949e' stroke-width='2'%3E%3Ccircle cx='11' cy='11' r='8'/%3E%3Cpath d='m21 21-4.35-4.35'/%3E%3C/svg%3E"); background-repeat: no-repeat; background-position: 10px center; }
  .search-input:focus { border-color: var(--accent); }
  .search-input::placeholder { color: var(--text-dim); }
  .chapter-count { font-family: 'DM Mono', monospace; font-size: 11px; color: var(--text-muted); white-space: nowrap; }
  .stats-strip { display: grid; grid-template-columns: repeat(auto-fit, minmax(180px, 1fr)); gap: 12px; margin-bottom: 48px; }
  .stat-card { background: var(--surface); border: 1px solid var(--border); border-radius: 10px; padding: 16px 18px; transition: border-color 0.2s, transform 0.2s; }
  .stat-card:hover { border-color: var(--accent); transform: translateY(-2px); }
  .stat-label { font-family: 'DM Mono', monospace; font-size: 10px; text-transform: uppercase; letter-spacing: 0.1em; color: var(--text-muted); margin-bottom: 6px; }
  .stat-value { font-family: 'Playfair Display', serif; font-size: 22px; font-weight: 700; color: var(--accent); }
  .stat-desc { font-size: 12px; color: var(--text-muted); margin-top: 2px; }
  .hiyield { background: linear-gradient(135deg, rgba(232,164,74,0.08), rgba(232,164,74,0.03)); border: 1px solid rgba(232,164,74,0.25); border-left: 3px solid var(--accent); border-radius: 10px; padding: 20px 24px; margin-bottom: 48px; }
  .hiyield-header { display: flex; align-items: center; gap: 8px; font-family: 'DM Mono', monospace; font-size: 11px; text-transform: uppercase; letter-spacing: 0.12em; color: var(--accent); margin-bottom: 14px; }
  .hiyield ul { list-style: none; display: grid; grid-template-columns: repeat(auto-fill, minmax(300px, 1fr)); gap: 8px; }
  .hiyield ul li { font-size: 13px; color: var(--text); padding-left: 16px; position: relative; line-height: 1.5; }
  .hiyield ul li::before { content: '‚ñ∏'; position: absolute; left: 0; color: var(--accent); font-size: 11px; }
  strong.hl  { color: var(--accent);  font-weight: 600; }
  strong.hl2 { color: var(--accent2); font-weight: 600; }
  strong.hl3 { color: var(--accent3); font-weight: 600; }
  strong.hld { color: var(--danger);  font-weight: 600; }
  .section-label { font-family: 'DM Mono', monospace; font-size: 11px; text-transform: uppercase; letter-spacing: 0.14em; color: var(--text-muted); margin-bottom: 16px; display: flex; align-items: center; gap: 10px; }
  .section-label::after { content: ''; flex: 1; height: 1px; background: var(--border); }
  .chapters-grid { display: flex; flex-direction: column; gap: 12px; margin-bottom: 48px; }
  .chapter-card { background: var(--surface); border: 1px solid var(--border); border-radius: 12px; overflow: hidden; transition: border-color 0.2s, box-shadow 0.2s; }
  .chapter-card:hover { border-color: rgba(92,170,238,0.4); box-shadow: 0 4px 20px rgba(0,0,0,0.3); }
  .chapter-header { display: flex; align-items: center; gap: 14px; padding: 16px 20px; cursor: pointer; user-select: none; }
  .ch-num { font-family: 'DM Mono', monospace; font-size: 11px; font-weight: 500; color: var(--text-muted); background: var(--surface2); border: 1px solid var(--border); border-radius: 6px; padding: 3px 8px; white-space: nowrap; min-width: 52px; text-align: center; }
  .ch-title { flex: 1; font-size: 15px; font-weight: 500; color: var(--text); }
  .ch-tags { display: flex; gap: 6px; flex-wrap: wrap; }
  .tag { font-family: 'DM Mono', monospace; font-size: 9px; text-transform: uppercase; letter-spacing: 0.08em; padding: 2px 7px; border-radius: 4px; border: 1px solid; }
  .tag-hiy  { color: var(--accent);  border-color: rgba(232,164,74,0.3);  background: rgba(232,164,74,0.08); }
  .tag-eth  { color: var(--accent2); border-color: rgba(92,170,238,0.3);  background: rgba(92,170,238,0.08); }
  .tag-soc  { color: var(--accent3); border-color: rgba(99,217,138,0.3);  background: rgba(99,217,138,0.08); }
  .tag-crit { color: var(--danger);  border-color: rgba(240,122,122,0.3); background: rgba(240,122,122,0.08); }
  .ch-toggle { color: var(--text-muted); font-size: 18px; transition: transform 0.3s; line-height: 1; }
  .chapter-card.open .ch-toggle { transform: rotate(180deg); }
  .chapter-body { display: none; padding: 0 20px 20px 20px; border-top: 1px solid var(--border); animation: slideIn 0.2s ease; }
  @keyframes slideIn { from { opacity: 0; transform: translateY(-6px); } to { opacity: 1; transform: translateY(0); } }
  .chapter-card.open .chapter-body { display: block; }
  .key-points { list-style: none; display: flex; flex-direction: column; gap: 6px; margin-top: 10px; }
  .key-points li { font-size: 13.5px; color: var(--text); padding: 8px 12px; background: var(--surface2); border-radius: 6px; border-left: 2px solid var(--border); line-height: 1.6; }
  .key-points li.imp  { border-left-color: var(--accent); }
  .key-points li.crit { border-left-color: var(--danger); }
  .key-points li.note { border-left-color: var(--accent2); }
  .mnemonic { margin-top: 12px; background: rgba(99,217,138,0.07); border: 1px dashed rgba(99,217,138,0.25); border-radius: 8px; padding: 10px 14px; font-size: 13px; color: var(--accent3); }
  .mnemonic::before { content: 'üí° '; }
  .progress-wrap { margin-bottom: 32px; }
  .progress-label { font-family: 'DM Mono', monospace; font-size: 11px; color: var(--text-muted); margin-bottom: 6px; display: flex; justify-content: space-between; }
  .progress-bar { height: 4px; background: var(--border); border-radius: 2px; overflow: hidden; }
  .progress-fill { height: 100%; background: linear-gradient(90deg, var(--accent), var(--accent2)); border-radius: 2px; width: 0%; transition: width 0.4s ease; }
  .footer { margin-top: 60px; padding-top: 24px; border-top: 1px solid var(--border); display: flex; justify-content: space-between; align-items: center; font-family: 'DM Mono', monospace; font-size: 11px; color: var(--text-dim); }
  .chapter-card.hidden { display: none; }
  @media (max-width: 600px) { .hero::after { font-size: 90px; } .stats-strip { grid-template-columns: repeat(2, 1fr); } .hiyield ul { grid-template-columns: 1fr; } .ch-tags { display: none; } }
</style>
</head>
<body>

<div class="search-bar">
  <div class="search-inner">
    <input class="search-input" type="text" id="searchInput" placeholder="Search chapters, topics, keywords‚Ä¶" oninput="filterChapters()">
    <span class="chapter-count" id="chapterCount">18 chapters</span>
  </div>
</div>

<div class="page-wrap">

  <div class="hero">
    <div class="hero-tag">Nelson Textbook of Pediatrics ¬∑ 22nd Edition ¬∑ 2024</div>
    <h1>Part <span>XII</span><br>Immunology</h1>
    <p class="hero-sub">The immune system in health and disease ‚Äî primary immunodeficiencies, autoinflammatory disorders, transplantation, and allergy/hypersensitivity reactions in children.</p>
    <div class="hero-meta">
      <span class="meta-pill"><span class="dot" style="background:var(--accent)"></span>Chapters 164‚Äì181</span>
      <span class="meta-pill"><span class="dot" style="background:var(--accent2)"></span>18 Chapters</span>
      <span class="meta-pill"><span class="dot" style="background:var(--accent3)"></span>High-Yield for Boards</span>
    </div>
  </div>

  <div class="stats-strip">
    <div class="stat-card"><div class="stat-label">Chapters</div><div class="stat-value">18</div><div class="stat-desc">Ch. 164‚Äì181</div></div>
    <div class="stat-card"><div class="stat-label">PID Categories</div><div class="stat-value">5</div><div class="stat-desc">B-cell ¬∑ T-cell ¬∑ Combined ¬∑ Phagocyte ¬∑ Complement</div></div>
    <div class="stat-card"><div class="stat-label">Key Syndromes</div><div class="stat-value">20+</div><div class="stat-desc">XLA, SCID, CGD, DiGeorge, WAS, CVID‚Ä¶</div></div>
    <div class="stat-card"><div class="stat-label">Board Relevance</div><div class="stat-value">‚òÖ‚òÖ‚òÖ‚òÖ‚òÖ</div><div class="stat-desc">PID pattern recognition heavily tested</div></div>
  </div>

  <div class="hiyield">
    <div class="hiyield-header">‚ö° High-Yield Quick Reference ‚Äî Part XII</div>
    <ul>
      <li>B-cell defects ‚Üí <strong class="hl">recurrent bacterial infections</strong> (encapsulated organisms) after 6 months (maternal IgG wanes)</li>
      <li>T-cell defects ‚Üí <strong class="hld">opportunistic infections</strong> (PCP, CMV, Candida, viral) from birth</li>
      <li>XLA (Bruton): absent B cells, ‚Üìall Ig, boys; presents ~6 months; treat with IVIG</li>
      <li>CVID: low IgG + IgA ¬± IgM; normal B-cell count; most common symptomatic PID in adults/older children</li>
      <li>SCID: absent T cells ¬± B cells ¬± NK; "bubble boy"; no live vaccines; treat with HSCT ASAP</li>
      <li>DiGeorge: 22q11.2 deletion; absent thymus ‚Üí ‚ÜìT cells; hypocalcemia + conotruncal heart defects</li>
      <li>Wiskott-Aldrich: X-linked; triad ‚Äî eczema + thrombocytopenia + recurrent infections; ‚ÜìIgM, ‚ÜëIgA/IgE</li>
      <li>Ataxia-telangiectasia: cerebellar ataxia + oculocutaneous telangiectasias + ‚ÜìIgA; ‚ÜëAFP; radiation sensitive; ‚Üëmalignancy</li>
      <li>CGD: NADPH oxidase defect; catalase-positive organisms (Staph, Aspergillus, Serratia, Nocardia, Burkholderia); NBT test (negative); treat with prophylactic TMP-SMX + itraconazole + IFN-Œ≥</li>
      <li>Complement deficiencies: C3 ‚Üí recurrent encapsulated bacteria; C5‚ÄìC9 (MAC) ‚Üí recurrent Neisseria (meningococcal, gonococcal)</li>
      <li>Hereditary angioedema (HAE): C1-inhibitor deficiency; recurrent angioedema without urticaria; treat acute with C1-INH concentrate or icatibant</li>
      <li>Graft-versus-host disease (GvHD): donor T cells attack host; skin (rash), liver (‚Üëbili), gut (diarrhea)</div>
    </ul>
  </div>

  <div class="progress-wrap">
    <div class="progress-label"><span>Study Progress</span><span id="progressText">0 / 18 opened</span></div>
    <div class="progress-bar"><div class="progress-fill" id="progressFill"></div></div>
  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION A: IMMUNE SYSTEM    -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section A ‚Äî The Immune System: Overview &amp; Development</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="innate adaptive immunity B cell T cell NK cell complement phagocyte neutrophil macrophage dendritic MHC antigen presentation cytokine lymphocyte development bone marrow thymus immunoglobulin">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 164</span>
        <span class="ch-title">The Immune System: Innate &amp; Adaptive Immunity</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">Innate immunity</strong>: immediate, non-specific; neutrophils, macrophages, NK cells, complement, physical barriers; pattern recognition via PRRs (Toll-like receptors)</li>
          <li class="imp"><strong class="hl">Adaptive immunity</strong>: specific, delayed (days); B cells (humoral ‚Äî antibodies) and T cells (cellular); immunological memory</li>
          <li class="imp">B-cell development: bone marrow ‚Üí mature naive B cell; activation ‚Üí plasma cells (antibody secretion) + memory B cells; requires T-cell help (CD4+ Th) for class switching</li>
          <li class="imp">T-cell development: bone marrow precursors ‚Üí <strong class="hl">thymus</strong> (positive + negative selection) ‚Üí CD4+ helper or CD8+ cytotoxic T cells</li>
          <li class="imp">MHC I (HLA-A, B, C): on all nucleated cells; present to <strong class="hl">CD8+ T cells</strong> (cytotoxic); endogenous antigens (viral, tumour)</li>
          <li class="imp">MHC II (HLA-DR, DQ, DP): on APCs (B cells, macrophages, dendritic cells); present to <strong class="hl">CD4+ T cells</strong> (helper); exogenous antigens</li>
          <li class="imp">Immunoglobulins: <strong class="hl">IgG</strong> (most abundant, crosses placenta, memory), <strong class="hl">IgA</strong> (mucosal, secretory ‚Äî colostrum, saliva, tears), <strong class="hl">IgM</strong> (first responder, pentamer, complement activation), <strong class="hl">IgE</strong> (allergy, parasites), <strong class="hl">IgD</strong> (B-cell receptor)</li>
          <li class="note">Maternal IgG crosses placenta ‚Üí protects neonate for first 6 months; then infant must produce own ‚Üí window of vulnerability for B-cell defects</li>
        </ul>
        <div class="mnemonic">MHC rule: "MHC I = CD8 kills; MHC II = CD4 helps" ‚Äî one number higher each time</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="approach immunodeficiency recurrent infections evaluation workup CBC immunoglobulin levels flow cytometry lymphocyte subsets T B NK DHR NBT complement CH50 AH50 vaccine response">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 165</span>
        <span class="ch-title">Approach to the Child with Suspected Immunodeficiency</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Warning signs of PID: ‚â•8 new ear infections/yr, ‚â•2 serious sinus infections/yr, ‚â•2 pneumonias/yr, failure to thrive, recurrent deep skin/organ abscesses, ‚â•2 deep-seated infections, persistent thrush, family history of PID, need for IV antibiotics to clear infection</li>
          <li class="imp">Key clue: <strong class="hl">organism type</strong> identifies defect ‚Äî encapsulated bacteria (B-cell); opportunistic/fungi/viral (T-cell); catalase-positive bacteria (phagocyte); Neisseria (complement C5‚ÄìC9)</li>
          <li class="imp">Age of onset: T-cell defects ‚Üí from birth; B-cell defects ‚Üí after 6 months (maternal IgG wanes)</li>
          <li class="imp">Initial workup: <strong class="hl">CBC + differential</strong> (lymphopenia ‚Üí T-cell defect; neutropenia; ‚Üìplatelets in WAS), serum immunoglobulins (IgG, IgA, IgM, IgE), <strong class="hl">flow cytometry</strong> (T/B/NK cell counts)</li>
          <li class="imp">Further testing: vaccine antibody titers (functional B cells), <strong class="hl">DHR/NBT test</strong> (phagocyte oxidative burst ‚Äî CGD), CH50/AH50 (complement), lymphocyte proliferation assays (T-cell function), HIV test</li>
          <li class="note">Live vaccines (MMR, varicella, rotavirus, BCG, yellow fever) CONTRAINDICATED in most PIDs ‚Äî risk of disseminated vaccine-strain infection</li>
          <li class="note">Family history: X-linked PIDs (XLA, SCID, WAS, CGD, XLP) affect males; AR PIDs affect both sexes</li>
        </ul>
        <div class="mnemonic">PID organism clues: "Bacteria = B-cell; Opportunists = T-cell; Catalase+ = Phagocyte; Neisseria = Complement (C5-C9)"</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION B: B-CELL DEFECTS   -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section B ‚Äî Predominantly B-Cell (Antibody) Deficiencies</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="XLA Bruton agammaglobulinemia X-linked BTK absent B cells panhypogammaglobulinemia recurrent sinopulmonary encapsulated bacteria Streptococcus Haemophilus IVIG enteroviral meningoencephalitis Giardia">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 166</span>
        <span class="ch-title">X-Linked Agammaglobulinemia (XLA / Bruton Disease)</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">XLA: <strong class="hl">BTK (Bruton tyrosine kinase)</strong> mutation ‚Üí arrest of B-cell development at pre-B stage ‚Üí <strong class="hl">absent B cells + absent/markedly ‚Üì all Ig classes</strong>; X-linked ‚Üí <strong class="hl">males only</strong></li>
          <li class="crit">Presentation: recurrent sinopulmonary infections after <strong class="hl">6 months</strong> (maternal IgG wanes); organisms: <strong class="hl">encapsulated bacteria</strong> (S. pneumoniae, H. influenzae, Staph aureus), Giardia, Mycoplasma</li>
          <li class="crit">Complications: <strong class="hl">enteroviral meningoencephalitis</strong> (echo/polio virus ‚Äî can be chronic/fatal without Ig); live polio vaccine contraindicated (use IPV)</li>
          <li class="imp">Lab: absent/very low B cells on flow cytometry, panhypogammaglobulinemia (IgG &lt;200 mg/dL), normal T-cell numbers and function</li>
          <li class="crit">Treatment: <strong class="hl">IVIG every 3‚Äì4 weeks for life</strong> (target trough IgG &gt;500‚Äì800 mg/dL); SCIG (subcutaneous) alternative; prophylactic antibiotics; no live vaccines</li>
          <li class="note">No tonsils/lymph nodes palpable (no B cells ‚Üí no germinal centers)</li>
        </ul>
        <div class="mnemonic">XLA: "Boys, No B cells, No Ig, No tonsils ‚Üí IVIG for life ‚Äî Bruton's BTK mutation"</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="CVID common variable immunodeficiency low IgG IgA IgM normal B cells autoimmunity granuloma lymphoma bronchiectasis IVIG recurrent sinopulmonary infections">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 167</span>
        <span class="ch-title">Common Variable Immunodeficiency (CVID)</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">CVID: most common <strong class="hl">symptomatic</strong> PID in adults and older children; onset usually 2nd‚Äì3rd decade; equal sex distribution</li>
          <li class="imp">Characteristics: <strong class="hl">‚ÜìIgG (most important) + ‚ÜìIgA and/or ‚ÜìIgM</strong>; normal or ‚ÜìB-cell numbers BUT poor antibody response to vaccines (dysfunctional B cells)</li>
          <li class="crit">Infections: recurrent sinopulmonary infections (S. pneumoniae, H. influenzae, Mycoplasma), Giardia, chronic lung disease (bronchiectasis)</li>
          <li class="imp">Non-infectious complications: <strong class="hl">autoimmune disease</strong> (ITP, AIHA, RA, IBD-like), <strong class="hl">granulomatous disease</strong> (lung, liver, spleen), <strong class="hl">‚Üëlymphoma risk</strong> (B-cell lymphomas), GI disease (malabsorption, IBD-like enteropathy), splenomegaly</li>
          <li class="crit">Treatment: <strong class="hl">IVIG/SCIG lifelong</strong>; monitor for complications; no live vaccines; treat autoimmune manifestations separately</li>
          <li class="note">Key distinction from XLA: CVID has <strong class="hl">normal B-cell numbers</strong> (dysfunctional), XLA has <strong class="hl">absent B cells</strong></li>
        </ul>
        <div class="mnemonic">CVID: "Normal B cells that Don't Work" ‚Äî low Ig despite having B cells; presents later than XLA</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="selective IgA deficiency most common PID anaphylaxis blood transfusion recurrent sinopulmonary Giardia celiac autoimmune low IgA normal IgG IgM">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 168</span>
        <span class="ch-title">Selective IgA Deficiency &amp; Other Antibody Deficiencies</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="crit"><strong class="hld">Selective IgA deficiency</strong>: <strong class="hld">most common PID overall</strong> (1/300‚Äì700); IgA &lt;7 mg/dL with normal IgG and IgM; most asymptomatic</li>
          <li class="imp">Symptomatic: recurrent sinopulmonary infections (S. pneumoniae, H. influenzae), Giardia, celiac disease (‚Üëassociation), autoimmune disease (‚ÜëSLE, RA, thyroid disease)</li>
          <li class="crit"><strong class="hld">Anaphylaxis to blood products</strong>: anti-IgA antibodies in IgA-deficient patients ‚Üí severe transfusion reactions; must use <strong class="hl">IgA-depleted blood products</strong> or washed RBCs</li>
          <li class="note">IVIG contraindicated (contains IgA ‚Üí anaphylaxis risk); no specific treatment; treat infections aggressively</li>
          <li class="note"><strong class="hl">Transient hypogammaglobulinemia of infancy</strong>: physiologic nadir of IgG at 3‚Äì6 months prolonged beyond 6 months; self-resolves by 2‚Äì4 yrs; usually mild infections; watch and wait</li>
          <li class="note"><strong class="hl">Hyper-IgM syndrome</strong>: ‚ÜëIgM, ‚ÜìIgG/A/E; defect in CD40L (X-linked) or CD40/AID ‚Üí cannot class-switch; Pneumocystis jirovecii pneumonia (PCP) risk (T-cell co-signal needed); treat with IVIG + TMP-SMX prophylaxis</li>
        </ul>
        <div class="mnemonic">IgA deficiency: "Most Common PID, Usually Silent, Anaphylaxis to blood products ‚Äî use IgA-depleted products"</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION C: T-CELL & COMBINED DEFECTS -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section C ‚Äî T-Cell &amp; Combined Immunodeficiencies</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="SCID severe combined immunodeficiency bubble boy absent T cells B cells NK ADA RAG gamma chain IL-2 receptor PCP Candida viral infections HSCT gene therapy no live vaccines lymphopenia">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 169</span>
        <span class="ch-title">Severe Combined Immunodeficiency (SCID)</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="crit">SCID: <strong class="hld">medical emergency</strong>; absent T cells ¬± B cells ¬± NK cells ‚Üí profound susceptibility to ALL infections; without treatment ‚Üí death within 1st year</li>
          <li class="imp">Most common form: <strong class="hl">X-linked SCID</strong> (Œ≥-chain of IL-2 receptor mutation ‚Üí ‚ÜìIL-2/4/7/9/15/21 signaling; T‚ÅªB‚Å∫NK‚Åª); males; most common overall SCID type</li>
          <li class="imp">Other forms: <strong class="hl">ADA deficiency</strong> (adenosine deaminase; AR; T‚ÅªB‚ÅªNK‚Åª; toxic deoxyadenosine accumulates; treat with PEG-ADA enzyme replacement or gene therapy); <strong class="hl">RAG1/2 deficiency</strong> (T‚ÅªB‚ÅªNK‚Å∫)</li>
          <li class="crit">Presentation: failure to thrive, recurrent/severe infections from birth ‚Äî PCP (<em>Pneumocystis</em>), CMV, RSV, parainfluenza, Candida, persistent mucocutaneous candidiasis; chronic diarrhea, absent lymph nodes/thymus</li>
          <li class="crit"><strong class="hld">Newborn screening</strong>: TREC (T-cell receptor excision circles) assay detects SCID at birth before infections occur ‚Äî now in all US states; most important advance</li>
          <li class="crit">Treatment: <strong class="hld">HSCT (hematopoietic stem cell transplant) ASAP</strong> ‚Äî curative; best outcomes if performed before 3.5 months of age; gene therapy (for ADA, X-SCID) increasingly available</li>
          <li class="crit">ABSOLUTE contraindications: <strong class="hld">NO live vaccines</strong> (BCG, MMR, varicella, rotavirus ‚Äî fatal disseminated disease); <strong class="hld">irradiate ALL blood products</strong> (prevent transfusion-associated GvHD)</li>
          <li class="note">Maternal T-cell engraftment: maternal T cells can engraft in SCID ‚Üí GvHD-like picture (erythroderma, ‚Üëliver enzymes)</li>
        </ul>
        <div class="mnemonic">SCID: "No T cells ‚Üí No Immunity ‚Üí No Live Vaccines ‚Üí HSCT Now!" ‚Äî TREC screen catches it at birth</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="DiGeorge syndrome 22q11 thymic aplasia T-cell deficiency hypocalcemia conotruncal heart defect CATCH-22 FISH microarray partial complete thymus transplant">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 170</span>
        <span class="ch-title">DiGeorge Syndrome (22q11.2 Deletion) ‚Äî Immunologic Aspects</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">DiGeorge: 22q11.2 microdeletion ‚Üí failure of 3rd and 4th pharyngeal pouches to develop ‚Üí thymic aplasia/hypoplasia ‚Üí ‚ÜìT cells</li>
          <li class="imp">Spectrum: <strong class="hl">partial DiGeorge</strong> (mild ‚ÜìT cells, most common; usually manageable) vs <strong class="hl">complete DiGeorge</strong> (absent thymus ‚Üí SCID-like; requires thymus transplant)</li>
          <li class="imp">CATCH-22 features (see Part VIII): Cardiac (conotruncal), Abnormal facies, Thymic aplasia, Cleft palate, Hypocalcemia (hypoparathyroidism), 22q11</li>
          <li class="crit">Immunologic complications: recurrent viral/fungal infections (‚ÜìT cells), poor vaccine responses; complete DiGeorge ‚Üí opportunistic infections identical to SCID</li>
          <li class="crit">Treatment: complete DiGeorge ‚Üí <strong class="hl">thymus transplant</strong> (cultured thymic tissue); calcium + calcitriol for hypocalcemia; cardiac surgery; no live vaccines in complete form</li>
          <li class="note">Psychiatric complications: schizophrenia (25‚Äì30%), anxiety, ADHD, autism ‚Äî monitor through life</li>
        </ul>
        <div class="mnemonic">DiGeorge: "No Thymus ‚Üí No T cells ‚Üí Opportunistic infections + Hypocalcemia + Heart defects = 22q11"</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="Wiskott-Aldrich syndrome WAS X-linked WASp eczema thrombocytopenia recurrent infections small platelets IgM low IgA IgE high HSCT lymphoma EBV">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 171</span>
        <span class="ch-title">Wiskott-Aldrich Syndrome (WAS)</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="crit">WAS: <strong class="hl">WASp (Wiskott-Aldrich Syndrome protein)</strong> mutation; X-linked ‚Üí males; WASp required for actin cytoskeleton remodeling in immune cells</li>
          <li class="crit">Classic triad: <strong class="hld">Eczema + Thrombocytopenia + Recurrent infections</strong> (sinopulmonary, opportunistic)</li>
          <li class="imp">Immunology: combined B + T cell defect; <strong class="hl">‚ÜìIgM, ‚ÜëIgA, ‚ÜëIgE, normal/‚ÜìIgG</strong>; poor response to polysaccharide antigens; ‚ÜìT-cell function over time</li>
          <li class="crit">Platelets: <strong class="hld">small platelets (‚ÜìMPV)</strong> + thrombocytopenia ‚Üí bleeding (petechiae, bloody diarrhea, intracranial hemorrhage); characteristic small platelet size distinguishes from ITP</li>
          <li class="imp">Complications: autoimmunity (vasculitis, ITP, hemolytic anemia), ‚Üërisk EBV-associated lymphoma, infections (encapsulated bacteria, herpesvirus, PCP)</li>
          <li class="crit">Treatment: <strong class="hl">HSCT</strong> ‚Äî curative; IVIG; prophylactic TMP-SMX (PCP); splenectomy ‚Üëplatelet count (but ‚Üëinfection risk); gene therapy emerging</li>
        </ul>
        <div class="mnemonic">WAS triad: "WET" ‚Üí (W)iskott = Welt/Eczema, (E)czema, (T)hrombocytopenia + infections ‚Äî small platelets key!</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="ataxia telangiectasia AT cerebellar ataxia oculocutaneous telangiectasia ATM kinase low IgA IgG AFP elevated malignancy radiation sensitivity sinopulmonary infections DNA repair">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 172</span>
        <span class="ch-title">Ataxia-Telangiectasia (AT)</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">AT: <strong class="hl">ATM gene</strong> (DNA damage repair kinase) mutation; AR; defective DNA double-strand break repair ‚Üí genome instability</li>
          <li class="crit">Classic features: <strong class="hld">progressive cerebellar ataxia</strong> (onset 1‚Äì4 yrs, wheelchair by 10‚Äì12 yrs) + <strong class="hld">oculocutaneous telangiectasias</strong> (conjunctiva, ears, skin ‚Äî appear 3‚Äì6 yrs) + recurrent sinopulmonary infections</li>
          <li class="imp">Immunology: combined defect ‚Äî <strong class="hl">‚ÜìIgA (most common Ig deficiency)</strong>, ‚ÜìIgG subclasses, ‚ÜìT-cell function; lymphopenia</li>
          <li class="crit"><strong class="hld">‚ÜëAFP (alpha-fetoprotein)</strong>: hallmark lab finding; elevated due to defective DNA repair in hepatocytes; useful diagnostic marker</li>
          <li class="crit"><strong class="hld">Radiation sensitivity</strong>: ATM needed to repair radiation-induced DNA breaks; avoid X-rays/CT when possible; <strong class="hld">‚Üëmalignancy risk</strong> (lymphoma, leukemia, breast cancer in carriers)</li>
          <li class="note">No curative treatment; supportive care, IVIG if recurrent infections, physical/occupational therapy; avoid radiation</li>
        </ul>
        <div class="mnemonic">AT: "ATA" ‚Üí Ataxia, Telangiectasia, ‚ÜëAFP ‚Äî plus radiation sensitivity and ‚Üëcancer risk</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="hyper IgE syndrome Job syndrome STAT3 DOCK8 eczema recurrent Staph abscess pneumonia pneumatocele coarse facies retained primary teeth eosinophilia high IgE cold abscess">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 173</span>
        <span class="ch-title">Hyper-IgE Syndrome (Job Syndrome) &amp; Other Combined Defects</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Hyper-IgE syndrome (HIES / Job syndrome): <strong class="hl">STAT3 mutation</strong> (AD) most common; very high serum IgE (&gt;2000 IU/mL), eosinophilia</li>
          <li class="crit">Classic triad: <strong class="hld">"FATED"</strong> ‚Äî <strong class="hl">F</strong>acies (coarse), <strong class="hl">A</strong>bscesses (recurrent "cold" ‚Äî Staph aureus ‚Äî lack warmth/redness due to deficient neutrophil recruitment), <strong class="hl">T</strong>eeth (retained primary teeth), <strong class="hl">E</strong>czema, <strong class="hl">D</strong>ermatitis</li>
          <li class="imp">Pulmonary: recurrent Staph pneumonia ‚Üí <strong class="hl">pneumatoceles</strong> (lung cysts); Aspergillus superinfection of pneumatoceles</li>
          <li class="imp">Skeletal: scoliosis, hyperextensible joints, minimal trauma fractures, characteristic face (broad nasal bridge, deep-set eyes)</li>
          <li class="note">DOCK8 deficiency (AR HIES): severe eczema, viral skin infections (molluscum, HPV, HSV), Candida, T-cell lymphopenia; treat with HSCT</li>
          <li class="note">Treatment: TMP-SMX prophylaxis (Staph); antifungal prophylaxis; IVIG; no curative therapy for STAT3-HIES</li>
        </ul>
        <div class="mnemonic">Job syndrome: "FATED" ‚Üí Facies, cold Abscesses, Teeth (retained), Eczema, Dermatitis + pneumatoceles</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION D: PHAGOCYTE DEFECTS -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section D ‚Äî Phagocyte Defects</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="chronic granulomatous disease CGD NADPH oxidase gp91phox catalase positive organisms Staph Aspergillus Serratia Nocardia Burkholderia NBT DHR dihydrorhodamine nitroblue tetrazolium TMP-SMX itraconazole interferon gamma IFN granuloma">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 174</span>
        <span class="ch-title">Chronic Granulomatous Disease (CGD)</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">CGD: defective <strong class="hl">NADPH oxidase</strong> ‚Üí phagocytes cannot produce reactive oxygen species (oxidative burst) ‚Üí failure to kill catalase-positive organisms</li>
          <li class="imp">Most common form: X-linked (gp91phox subunit, 70%); also AR forms</li>
          <li class="crit">Susceptible organisms: <strong class="hld">catalase-positive</strong> (destroy their own H‚ÇÇO‚ÇÇ, so CGD phagocytes get no oxidative help): <strong class="hl">Staphylococcus aureus, Aspergillus (most common fungal), Serratia marcescens, Nocardia, Burkholderia cepacia, Candida</strong></li>
          <li class="crit">Presentations: recurrent skin/lymph node/liver/lung abscesses, osteomyelitis, pneumonia; granuloma formation (GI/GU obstruction from granulomas)</li>
          <li class="crit">Diagnosis: <strong class="hld">DHR (dihydrorhodamine) flow cytometry</strong> ‚Äî gold standard; or <strong class="hl">NBT (nitroblue tetrazolium) test</strong> ‚Äî normal neutrophils turn blue (reduce NBT); CGD = no color change (no oxidative burst)</li>
          <li class="crit">Treatment: prophylaxis ‚Äî <strong class="hl">TMP-SMX (bacterial) + itraconazole (fungal) + IFN-Œ≥ (‚Üëoxidative activity)</strong>; HSCT curative; gene therapy trials</li>
          <li class="note">Female carriers of X-linked CGD: mosaic DHR result (some normal, some abnormal neutrophils); usually asymptomatic but ‚Üërisk discoid lupus</li>
        </ul>
        <div class="mnemonic">CGD organisms: "NASSB" ‚Üí Nocardia, Aspergillus, Staph aureus, Serratia, Burkholderia ‚Äî all catalase-positive</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="leukocyte adhesion deficiency LAD CD18 CD11 integrins delayed umbilical cord separation omphalitis recurrent bacterial infections no pus neutrophilia elevated WBC leukocytosis">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 175</span>
        <span class="ch-title">Leukocyte Adhesion Deficiency (LAD) &amp; Other Phagocyte Defects</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="crit"><strong class="hld">LAD type I</strong>: CD18 (Œ≤‚ÇÇ integrin) deficiency ‚Üí neutrophils cannot adhere to endothelium ‚Üí cannot migrate to sites of infection; AR</li>
          <li class="crit">Classic hallmarks: <strong class="hld">delayed separation of umbilical cord (&gt;3 weeks)</strong>, recurrent omphalitis/skin infections, severe periodontitis, recurrent bacterial infections WITHOUT pus formation (no neutrophil extravasation)</li>
          <li class="crit">Labs: <strong class="hld">markedly elevated WBC/neutrophils</strong> during infections (neutrophils cannot leave bloodstream); absent CD18 on flow cytometry</li>
          <li class="imp">Treatment: HSCT (curative); prophylactic antibiotics; aggressive treatment of infections</li>
          <li class="note"><strong class="hl">Chediak-Higashi syndrome</strong>: AR; LYST gene; giant lysosomes in all granule-containing cells ‚Üí partial albinism, recurrent Staph/Strep infections, neutropenia, NK cell dysfunction, progressive neurologic deterioration; peripheral smear: giant granules in neutrophils; treat with HSCT</li>
          <li class="note"><strong class="hl">Cyclic neutropenia</strong>: ELANE mutation; neutropenia cycling every ~21 days; fever, oral ulcers, infections at nadir; treat with G-CSF</li>
        </ul>
        <div class="mnemonic">LAD: "Delayed cord separation + No pus + High WBC = can't migrate out of blood" ‚Äî CD18 missing</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION E: COMPLEMENT       -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section E ‚Äî Complement Deficiencies</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="complement deficiency C1q C2 C3 C4 C5 C6 C7 C8 C9 MAC Neisseria meningococcal gonococcal recurrent SLE lupus CH50 AH50 hereditary angioedema HAE C1 inhibitor bradykinin">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 176</span>
        <span class="ch-title">Complement Deficiencies &amp; Hereditary Angioedema</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Complement pathways: <strong class="hl">Classical</strong> (C1q, C4, C2, C3 ‚Üí C3b opsonization ‚Üí C5-C9 MAC) activated by Ab-Ag complexes; <strong class="hl">Alternative</strong> (Factor B, D, Properdin) ‚Äî spontaneous; <strong class="hl">Lectin</strong> (MBL)</li>
          <li class="imp"><strong class="hl">C3 deficiency</strong>: most severe complement deficiency; recurrent infections with <strong class="hl">encapsulated bacteria</strong> (S. pneumoniae, H. influenzae, Neisseria) from all pathways disrupted; ‚Üëautoimmune disease (SLE-like)</li>
          <li class="crit"><strong class="hld">C5‚ÄìC9 (MAC/terminal complement) deficiency</strong>: specific susceptibility to <strong class="hld">Neisseria</strong> (N. meningitidis, N. gonorrhoeae) ‚Äî recurrent meningococcal/gonococcal disease; MAC needed to lyse Gram-negative organisms with thin peptidoglycan</li>
          <li class="imp"><strong class="hl">C1q, C2, C4 deficiency</strong>: ‚ÜëSLE risk (complement needed to clear immune complexes); C2 deficiency is most common complement deficiency in whites</li>
          <li class="crit"><strong class="hld">Hereditary Angioedema (HAE)</strong>: <strong class="hl">C1-inhibitor (C1-INH) deficiency</strong> (AD) ‚Üí uncontrolled bradykinin generation ‚Üí episodic angioedema of skin, GI tract, larynx (life-threatening)</li>
          <li class="crit">HAE characteristics: <strong class="hld">NO urticaria</strong> (distinguishes from allergic angioedema); attacks triggered by stress/trauma/estrogen/ACE inhibitors; lab: ‚ÜìC4 (always low between attacks), ‚ÜìC1-INH level or function</li>
          <li class="crit">HAE acute treatment: <strong class="hld">C1-INH concentrate</strong> (Berinert/Cinryze), <strong class="hl">icatibant</strong> (bradykinin B2 receptor antagonist), or kallikrein inhibitor (ecallantide); epinephrine and antihistamines are NOT effective</li>
          <li class="imp">HAE prophylaxis: danazol (‚ÜëC1-INH synthesis), tranexamic acid, lanadelumab (anti-kallikrein monoclonal Ab)</li>
          <li class="note">Screen: CH50 (classical pathway) ‚Äî low if any classical pathway complement missing; AH50 (alternative pathway)</li>
        </ul>
        <div class="mnemonic">Complement deficiency key: "C3 = all bugs; C5-C9 = Neisseria only; C1/C2/C4 = SLE risk; C1-INH deficiency = HAE (no urticaria!)"</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION F: AUTOINFLAMMATORY -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section F ‚Äî Autoinflammatory &amp; Autoimmune Disorders</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="autoinflammatory periodic fever PFAPA FMF familial Mediterranean fever CAPS TRAPS HIDS inflammasome IL-1 colchicine anakinra canakinumab rilonacept">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 177</span>
        <span class="ch-title">Autoinflammatory Diseases &amp; Periodic Fever Syndromes</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Autoinflammatory diseases: innate immune dysregulation ‚Üí recurrent fever + inflammation without autoantibodies or antigen-specific T cells; most involve inflammasome/IL-1Œ≤ pathway</li>
          <li class="crit"><strong class="hld">PFAPA</strong> (Periodic Fever, Aphthous stomatitis, Pharyngitis, Adenitis): most common periodic fever syndrome in children; regular cycles every 3‚Äì5 wks; responds dramatically to <strong class="hl">single dose corticosteroid</strong>; tonsillectomy often curative; no genetic cause identified</li>
          <li class="crit"><strong class="hld">FMF (Familial Mediterranean Fever)</strong>: <strong class="hl">MEFV (pyrin)</strong> gene mutation; AR; Mediterranean/Middle Eastern populations; episodic fever + serositis (peritonitis, pleuritis, arthritis) lasting 12‚Äì72h; <strong class="hld">amyloidosis</strong> (AA type ‚Äî most serious complication ‚Üí renal failure); treat with <strong class="hl">colchicine (daily, lifelong)</strong> ‚Äî prevents attacks and amyloidosis</li>
          <li class="imp"><strong class="hl">CAPS</strong> (Cryopyrin-Associated Periodic Syndromes): NLRP3/cryopyrin mutations ‚Üí ‚ÜëIL-1Œ≤; spectrum from FCAS (cold urticaria) ‚Üí MWS (urticaria + deafness) ‚Üí NOMID (most severe ‚Äî neonatal onset, chronic meningitis, joint deformity); treat with <strong class="hl">IL-1 inhibitors</strong> (anakinra, canakinumab, rilonacept)</li>
          <li class="imp"><strong class="hl">TRAPS</strong> (TNF Receptor-Associated Periodic Syndrome): TNFRSF1A mutation; AD; prolonged fevers (&gt;1 wk); migratory rash, periorbital edema, myalgia; treat with etanercept or IL-1 inhibitors</li>
          <li class="note"><strong class="hl">HIDS</strong> (Hyper-IgD Syndrome): MVK (mevalonate kinase) mutation; AR; very ‚ÜëIgD; periodic fever + LAD + abdominal pain + rash; treat with IL-1 inhibitors</li>
        </ul>
        <div class="mnemonic">FMF: "Mediterranean Fever ‚Üí Peritonitis + Colchicine daily ‚Üí prevents Amyloidosis" ‚Äî MEFV gene</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="immune dysregulation IPEX syndrome APECED APS1 regulatory T cell FOXP3 autoimmune polyendocrinopathy enteropathy HLH hemophagocytic lymphohistiocytosis macrophage activation syndrome MAS ferritin cytokine storm">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 178</span>
        <span class="ch-title">Immune Dysregulation: IPEX, HLH &amp; Related Disorders</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="crit"><strong class="hld">HLH (Hemophagocytic Lymphohistiocytosis)</strong>: life-threatening cytokine storm from uncontrolled macrophage/T-cell activation; primary (genetic ‚Äî perforin/UNC13D/RAB27A mutations) or secondary (infection ‚Äî EBV most common, MAS in rheumatic disease, malignancy)</li>
          <li class="crit">HLH diagnostic criteria (‚â•5 of 8): fever, <strong class="hl">splenomegaly</strong>, ‚Üì2 cell lines (cytopenia), <strong class="hld">‚Üëferritin (&gt;500, often &gt;10,000)</strong>, ‚Üëtriglycerides/‚Üìfibrinogen, hemophagocytosis on BM biopsy, ‚ÜìNK cell activity, ‚ÜësCD25 (soluble IL-2R)</li>
          <li class="crit">Treatment: <strong class="hl">HLH-94/2004 protocol</strong> ‚Äî dexamethasone + etoposide ¬± cyclosporine; HSCT for primary/refractory HLH; treat underlying trigger</li>
          <li class="crit"><strong class="hld">IPEX syndrome</strong>: <strong class="hl">FOXP3</strong> mutation ‚Üí absent regulatory T cells (Tregs) ‚Üí uncontrolled autoimmunity; X-linked; neonatal onset triad: <strong class="hl">I</strong>mmune dysregulation (autoimmune enteropathy, diabetes, thyroiditis, hemolytic anemia), <strong class="hl">P</strong>olyendocrinopathy, <strong class="hl">E</strong>nteropathy, <strong class="hl">X</strong>-linked</li>
          <li class="imp">IPEX features: intractable diarrhea (enteropathy), type 1 diabetes (neonatal), eczema, severe failure to thrive; fatal without HSCT</li>
          <li class="note"><strong class="hl">APECED/APS-1</strong>: AIRE gene mutation (AR) ‚Üí failure of central tolerance ‚Üí autoimmune polyendocrinopathy (hypoparathyroidism + adrenal insufficiency + mucocutaneous candidiasis) ‚Äî classic triad</li>
        </ul>
        <div class="mnemonic">HLH: "Fever + Big Spleen + Cytopenias + VERY HIGH ferritin = HLH" ‚Äî ferritin &gt;10,000 is highly suggestive</div>
      </div>
    </div>

  </div>

  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <!-- SECTION G: TRANSPLANTATION & ALLERGY -->
  <!-- ‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê‚ïê -->
  <div class="section-label">Section G ‚Äî Transplantation Immunology &amp; Allergy</div>
  <div class="chapters-grid">

    <div class="chapter-card" data-keywords="HSCT hematopoietic stem cell transplant bone marrow transplant GvHD graft versus host disease rejection engraftment conditioning myeloablative immunosuppression tacrolimus cyclosporine solid organ transplant HLA matching">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 179</span>
        <span class="ch-title">Hematopoietic Stem Cell &amp; Solid Organ Transplantation</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">HSCT indications: SCID, WAS, CGD, thalassemia, sickle cell disease, leukemia, MPS I, aplastic anemia; conditioning (chemo ¬± radiation) ‚Üí destroy host immune system ‚Üí donor stem cells engraft</li>
          <li class="crit"><strong class="hld">GvHD (Graft-versus-Host Disease)</strong>: donor T cells recognize host alloantigens as foreign ‚Üí attack host tissues</li>
          <li class="crit">Acute GvHD (&lt;100 days): <strong class="hl">skin</strong> (maculopapular rash ‚Äî often first sign), <strong class="hl">liver</strong> (‚Üëbilirubin, ‚ÜëLFTs), <strong class="hl">GI tract</strong> (secretory diarrhea, cramping, bleeding); graded I‚ÄìIV; treat with steroids</li>
          <li class="imp">Chronic GvHD (&gt;100 days): resembles autoimmune disease ‚Äî scleroderma-like skin changes, sicca syndrome, bronchiolitis obliterans, cytopenias; treat with steroids + immunosuppression</li>
          <li class="imp">GvL (Graft-versus-Leukemia) effect: donor T cells also kill residual leukemia cells ‚Äî beneficial; balance against GvHD</li>
          <li class="imp">Rejection (solid organ): host immune system attacks donor organ; hyperacute (&lt;24h ‚Äî Ab-mediated, preformed), acute (days‚Äìweeks ‚Äî T-cell mediated), chronic (months‚Äìyears ‚Äî fibrosis)</li>
          <li class="note">Immunosuppression post-transplant: calcineurin inhibitors (tacrolimus, cyclosporine), mycophenolate, steroids; ‚Üëinfection risk (PCP prophylaxis, CMV monitoring, annual flu vaccine)</li>
        </ul>
        <div class="mnemonic">Acute GvHD targets: "Skin, Liver, Gut" ‚Äî donor T cells attack these three organs first</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="allergic rhinitis asthma atopic dermatitis eczema food allergy IgE mast cell histamine Th2 sensitization allergen immunotherapy pollen dust mite skin prick test RAST allergy testing antihistamine LTRA">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 180</span>
        <span class="ch-title">Allergic Diseases: Rhinitis, Atopic Dermatitis &amp; Food Allergy</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp">Atopic triad: <strong class="hl">atopic dermatitis (eczema) ‚Üí allergic rhinitis ‚Üí asthma</strong> ("atopic march"); IgE-mediated Th2 responses; strong genetic component</li>
          <li class="imp"><strong class="hl">Allergic rhinitis</strong>: seasonal (tree/grass/weed pollen) or perennial (dust mite, pet dander, mold); sneezing, rhinorrhea, nasal congestion, pruritus; "allergic salute," "allergic shiners," nasal crease; treat with intranasal corticosteroids (first-line), antihistamines, LTRA (montelukast); allergen immunotherapy for persistent/severe</li>
          <li class="imp"><strong class="hl">Atopic dermatitis (eczema)</strong>: chronic pruritic inflammatory skin disease; filaggrin (FLG) gene mutations ‚Üí defective skin barrier; flexural distribution (antecubital/popliteal fossa) in children; treat: moisturizers + topical corticosteroids (first-line), tacrolimus/pimecrolimus (steroid-sparing), dupilumab (anti-IL-4RŒ±, moderate-severe)</li>
          <li class="crit"><strong class="hl">Food allergy</strong>: IgE-mediated (immediate ‚Äî anaphylaxis) or non-IgE (delayed ‚Äî FPIES, eosinophilic esophagitis); top 9 allergens: milk, egg, peanut, tree nuts, fish, shellfish, wheat, soy, sesame</li>
          <li class="imp">Food allergy diagnosis: skin prick test + specific IgE (RAST); <strong class="hl">oral food challenge</strong> is gold standard; component testing (peanut Ara h 2 = ‚Üëanaphylaxis risk)</li>
          <li class="imp">LEAP trial: early introduction of peanut (4‚Äì11 months) in high-risk infants (severe eczema/egg allergy) ‚Üí <strong class="hl">‚Üìpeanut allergy 80%</strong>; current AAP guidance: introduce peanut-containing foods early</li>
          <li class="note">Oral immunotherapy (OIT): increasing doses of allergen ‚Üí desensitization; FDA-approved for peanut (Palforzia); improves threshold but does not cure</li>
        </ul>
        <div class="mnemonic">Atopic March: "Eczema ‚Üí Rhinitis ‚Üí Asthma" ‚Äî each step builds on the last in atopic individuals</div>
      </div>
    </div>

    <div class="chapter-card" data-keywords="hypersensitivity reactions Gell Coombs type I IgE immediate type II cytotoxic type III immune complex serum sickness type IV delayed DTH contact dermatitis drug allergy penicillin Stevens Johnson TEN">
      <div class="chapter-header" onclick="toggleCard(this)">
        <span class="ch-num">Ch. 181</span>
        <span class="ch-title">Hypersensitivity Reactions &amp; Drug Allergy</span>
        <div class="ch-tags"><span class="tag tag-hiy">High Yield</span><span class="tag tag-crit">Critical</span></div>
        <span class="ch-toggle">‚åÑ</span>
      </div>
      <div class="chapter-body">
        <ul class="key-points">
          <li class="imp"><strong class="hl">Gell &amp; Coombs classification</strong>:</li>
          <li class="imp"><strong class="hl">Type I (Immediate/IgE-mediated)</strong>: mast cell degranulation ‚Üí histamine; urticaria, angioedema, anaphylaxis; onset minutes; examples: food allergy, penicillin anaphylaxis, latex allergy, insect sting</li>
          <li class="imp"><strong class="hl">Type II (Cytotoxic/Ab-mediated)</strong>: IgG/IgM against cell surface ‚Üí complement activation/ADCC; examples: hemolytic transfusion reaction, autoimmune hemolytic anemia, Goodpasture, ITP, neonatal HDN</li>
          <li class="imp"><strong class="hl">Type III (Immune complex)</strong>: antigen-antibody complexes deposit in tissues ‚Üí complement activation ‚Üí inflammation; examples: serum sickness (urticaria + arthritis + fever + LAD 7‚Äì21 days after exposure), SLE, post-strep GN, Arthus reaction</li>
          <li class="imp"><strong class="hl">Type IV (Delayed/T-cell mediated)</strong>: sensitized T cells ‚Üí cytokines; onset 48‚Äì72h; examples: contact dermatitis (poison ivy, nickel), TB tuberculin test (PPD), transplant rejection, granulomatous disease</li>
          <li class="crit"><strong class="hld">Serum sickness</strong>: type III; classic after cefaclor (most common antibiotic cause in children), anti-thymocyte globulin, rituximab; fever + arthralgia + urticaria 7‚Äì21 days post-exposure; treat with antihistamines + NSAIDs ¬± corticosteroids</li>
          <li class="crit"><strong class="hld">Stevens-Johnson Syndrome (SJS) / TEN</strong>: severe mucocutaneous drug reaction; T-cell mediated (type IV variant); SJS &lt;10% BSA, TEN &gt;30%; mucous membrane involvement; most common drugs: sulfonamides, anticonvulsants (phenytoin, carbamazepine, lamotrigine), allopurinol, NSAIDs; treat: stop offending drug, supportive care (burn unit), IVIG/cyclosporine debated</li>
          <li class="note">Penicillin allergy: true IgE-mediated allergy &lt;1% of those reporting allergy; skin testing can confirm; cross-reactivity with cephalosporins ~2% (not ~10% as historically stated)</li>
        </ul>
        <div class="mnemonic">4 Hypersensitivity Types: "ACID" ‚Üí Anaphylaxis (I/IgE), Cytotoxic (II/IgG), Immune complex (III/complement), Delayed (IV/T-cells)</div>
      </div>
    </div>

  </div>

  <div class="footer">
    <span>Nelson Textbook of Pediatrics ¬∑ 22nd Ed. ¬∑ 2024</span>
    <span>Part XII: Chapters 164‚Äì181 ¬∑ Immunology</span>
  </div>

</div>

<script>
  let openedChapters = new Set();
  const TOTAL_CHAPTERS = 18;

  function toggleCard(header) {
    const card = header.parentElement;
    const wasOpen = card.classList.contains('open');
    card.classList.toggle('open');
    const chNum = card.querySelector('.ch-num').textContent;
    if (!wasOpen) openedChapters.add(chNum);
    updateProgress();
  }

  function updateProgress() {
    const opened = openedChapters.size;
    const pct = Math.min((opened / TOTAL_CHAPTERS) * 100, 100);
    document.getElementById('progressFill').style.width = pct + '%';
    document.getElementById('progressText').textContent = `${opened} / ${TOTAL_CHAPTERS} opened`;
  }

  function filterChapters() {
    const q = document.getElementById('searchInput').value.toLowerCase().trim();
    const cards = document.querySelectorAll('.chapter-card');
    let visible = 0;
    cards.forEach(card => {
      const title    = card.querySelector('.ch-title').textContent.toLowerCase();
      const body     = card.querySelector('.chapter-body') ? card.querySelector('.chapter-body').textContent.toLowerCase() : '';
      const keywords = (card.dataset.keywords || '').toLowerCase();
      if (!q || title.includes(q) || body.includes(q) || keywords.includes(q)) {
        card.classList.remove('hidden'); visible++;
      } else { card.classList.add('hidden'); }
    });
    document.getElementById('chapterCount').textContent = q ? `${visible} result${visible !== 1 ? 's' : ''}` : `${TOTAL_CHAPTERS} chapters`;
  }

  document.addEventListener('keydown', e => {
    if (e.ctrlKey && e.key === 'e') {
      e.preventDefault();
      document.querySelectorAll('.chapter-card:not(.open)').forEach(c => {
        c.classList.add('open');
        openedChapters.add(c.querySelector('.ch-num').textContent);
      });
      updateProgress();
    }
  });
</script>
</body>
</html>
